Tuberculosis (TB) - HIV and Hepatitis.com

Tuberculosis (TB)

Articles on Tuberculosis

Guidelines: Treatment of Tuberculosis (6/20/2003)

Guidelines for Prevention and Treatment of Opportunistic Infections among HIV-Exposed and HIV-Infected Children (9/4/2009)

Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents (4/10/2009)

CDC Tuberculosis Fact Sheets

	General Information Basic TB information, Difference between latent TB & active TB disease,
	Data & Statistics TB trends, TB Genotyping, RVCT, NTIP...
	Drug-Resistant TB Multidrug-resistant TB (MDR TB), Extensively drug-resistant TB (XDR TB)
	Infection Control & Prevention Respiratory protection, Health-Care Settings, International Travelers...
	TB in Specific Populations TB & HIV, Pregnancy, International travelers
	Treatment Treatments regimens for latent TB infection & TB disease, Drug-resistant TB, TB & HIV...
	Testing & Diagnosis Tuberculin skin testing, QuantiFeron(R)-TB Gold Test, Diagnosis of TB
	Vaccines & Immunizations BCG Vaccine,

Articles on Tuberculosis
	Updated CDC HIV and TB Fact Sheet 6-28-2011
	Shorter Treatment More Effective for Latent TB 5-24-2011
	FDA Approves Rapid Test for MRSA 5-13-2011
	Study Finds No XMRV-Chronic Fatigue Link 5-10-2011
	TB Fixed-dose Coformulation Works as Well as Separate Drugs 4-15-2011
	Immediate ART Improves Survival for HIV+ People with TB 3-18-2011
	Tuberculosis Coinfection Increases Risk of Mother-to-Child HIV Transmission 2-01-2011
	Tuberculosis Late Diagnosis and Mortality Decrease among HIV Positive People in U.S. 12-14-2010
	More than 1 Million People Are Coinfected with HIV and Tuberculosis, WHO Report Says 11-19-2010
	Experimental Drug TMC207 Cuts Response Time for Multidrug-resistant Tuberculosis 10-04-2010
	New Tuberculosis Test Enables Fast and Accurate Diagnosis and Identification of Drug Resistance 9-10-2010
	FDA Drafts New Rules for Testing and Approval of Combination Regimens for Diseases such as Tuberculosis and HIV 3-26-2010
	Starting Antiretroviral Therapy during Tuberculosis Treatment Is Safer than Waiting, despite Potential Drug Interactions 3-26-2010
	World Health Organization Report Reveals Record Levels of Multidrug-resistant and Extensively Drug-resistant Tuberculosis 3-23-2010
	First Case of Extremely Drug-resistant Tuberculosis in the U.S. 1-5-2010
	Tuberculosis (TB): An Overview from the U.S. Centers for Disease Control and Prevention 12-04-09
	Is It Possible to Eliminate Tuberculosis? 10-23-2009
	Current Guidelines Need to Be Changed for Both First-line Treatment and Re-treatment of Tuberculosis, Experts Say 9-18-2009
	How Infectious Are Tuberculosis Patients Coinfected with HIV? 8-18-2009
	New Drug-resistant Tuberculosis Strains Could Become Widespread 8-18-2009
	IAS 2009 Opening Session Emphasizes Need for Expanded Treatment of HIV and Tuberculosis in Developing Countries 7-24-2009
	Research Offers Guidance on Scaling Up HIV and Tuberculosis Treatment Programs in Resource-limited Countries 7-24-2009
	Widespread Use of Antiretroviral Therapy Associated with a Large Decrease in Tuberculosis Prevalence in South Africa 7-24-2009
	World Health Organization (WHO) Says the BCG Tuberculosis Vaccine Is Too Dangerous for HIV Positive Infants 7-14-2009
	Laboratory Study Helps Explain Why People with HIV Are More Susceptible to Tuberculosis 7-10-2009
	TB Alliance and Tibotec Form Collaboration to Develop New Drugs for Tuberculosis 6-19-2009
	Promising Interim Results of a Study of TMC207, a New Experimental Drug for Treatment of Multidrug-resistant Tuberculosis (MDR-TB) 6-5-2009
	WHO Releases New Report on Tuberculosis and Its Impact on People with HIV/AIDS 3/31/09
	Preventive Isoniazid plus HAART Lowers the Risk of Active Tuberculosis among HIV Patients by 89% 3/31/09
	WHO Releases New Report on Tuberculosis and Its Impact on People with HIV/AIDS 3/27/09
	Preventive Isoniazid plus HAART Lowers the Risk of Active Tuberculosis among HIV Patients by 89% 3/27/09

	Multidrug-Resistant Tuberculosis (MDR TB) and Possible Effective Treatments MDR TB occurs when a Mycobacterium tuberculosis strain is resistant to isoniazid and rifampin, two of the most powerful first-line drugs. To cure MDR TB, healthcare providers must turn to a combination of second-line drugs, several of which are shown here.